MK-677 vs CJC-1295

Overview

MK-677 and CJC-1295 both aim to increase growth hormone levels but through fundamentally different mechanisms and administration routes. MK-677 is an oral non-peptide ghrelin mimetic, while CJC-1295 is an injectable GHRH analog. Neither is FDA-approved for clinical use.

This comparison matters because these compounds represent different approaches to GH secretion enhancement with distinct practical considerations.

Key Facts

Aspect	MK-677	CJC-1295
Also Known As	Ibutamoren	Tetrasubstituted GRF(1-29)
Class	Growth Hormone Secretagogue	GHRH Analog
Molecule Type	Non-peptide (small molecule)	Peptide
Administration	Oral	Injectable (subcutaneous)
FDA Status	Not approved	Not approved

Fundamental Differences

Aspect	MK-677	CJC-1295
Structure	Spiropiperidine compound	29-amino acid peptide
Target Receptor	GHS-R1a (Ghrelin receptor)	GHRH receptor
Mechanism	Mimics ghrelin	Mimics GHRH
Half-life	~24 hours	~8 days (with DAC) or ~30 min (no DAC)

MK-677 Mechanism

• Binds to ghrelin receptor (GHS-R1a)
• Stimulates GH release from pituitary
• Does not suppress natural GH pulsatility
• Also increases appetite via ghrelin pathway

CJC-1295 Mechanism

• GHRH analog with modified amino acids
• Acts directly on pituitary GHRH receptors
• Stimulates GH synthesis and release
• DAC version has extended half-life

CJC-1295 Variants

Variant	CJC-1295 DAC	CJC-1295 (no DAC)
Half-life	~8 days	~30 minutes
GH Pattern	Elevated baseline	Pulsatile
Also Called	CJC-1295 with DAC	Modified GRF(1-29), MOD-GRF

DAC = Drug Affinity Complex: Extends half-life through albumin binding.

GH Release Comparison

Aspect	MK-677	CJC-1295 (no DAC)	CJC-1295 DAC
GH Increase	Sustained elevation	Acute pulses	Sustained elevation
IGF-1 Effect	40-80% increase	Variable	40-100% increase
Pattern	Continuous	Pulsatile	Continuous

Research Data

MK-677 Studies:

• Shown to increase IGF-1 by 40-80% in clinical studies
• Maintains GH pulsatility pattern
• Effects persist with continued use
• Some human trial data exists

CJC-1295 Studies:

• Limited human data
• Shows GH and IGF-1 increases
• DAC version studied in clinical trials (halted)
• Non-DAC version less studied

Administration Comparison

Aspect	MK-677	CJC-1295
Route	Oral (tablet/capsule)	Subcutaneous injection
Convenience	High	Lower
Stability	Stable	Requires reconstitution
Storage	Room temperature	Refrigerated (reconstituted)

Side Effect Profile

MK-677 Side Effects

Effect	Frequency	Notes
Increased Appetite	Very common	Ghrelin pathway
Water Retention	Common	Can be significant
Blood Glucose Elevation	Common	May impair glucose tolerance
Lethargy/Fatigue	Common	Often initial
Numbness/Tingling	Occasional	Carpal tunnel-like

CJC-1295 Side Effects

Effect	Frequency	Notes
Injection Site Reactions	Common	Redness, swelling
Flushing	Common	Facial/warm sensation
Headache	Occasional	Usually transient
Water Retention	Possible	Less than MK-677
Blood Glucose	Possible	Less pronounced

Comparative Side Effects

Side Effect	MK-677	CJC-1295
Appetite Increase	Significant	Minimal
Water Retention	More	Less
Glucose Effects	More concerning	Less concerning
Convenience Tradeoff	No injections	Requires injections

Evidence Quality

Factor	MK-677	CJC-1295
Human Trials	Multiple (Phase 2)	Limited
Duration	Up to 2 years	Short-term
Publication Quality	Moderate	Low
Regulatory Review	Incomplete	None

MK-677 Research History

• Developed by Merck
• Reached Phase 2 trials for various indications
• Development discontinued (commercial reasons)
• Some peer-reviewed human data exists

CJC-1295 Research History

• Developed by ConjuChem Biotechnologies
• DAC version in clinical trials
• Program halted after patient death (unrelated to drug per company)
• Limited published human data

Safety Considerations

Concern	MK-677	CJC-1295
Long-term GH elevation	Unknown risk	Unknown risk
Cancer risk	Theoretical	Theoretical
Diabetes risk	Elevated	Lower
Quality control	Variable	Variable

Specific Concerns

MK-677:

• Glucose metabolism impairment documented
• May not be suitable for pre-diabetics
• Long-term effects of chronic GH elevation unknown

CJC-1295:

• Less human safety data
• Clinical program discontinuation raises questions
• Purity concerns with research sources

Practical Considerations

Factor	MK-677	CJC-1295
Ease of Use	Very easy (oral)	Moderate (injection)
Acquisition	Research chemical	Research chemical
Quality Verification	Difficult	Difficult
Stacking	Often used alone	Often combined with GHRP

Common Research Combinations

CJC-1295 (no DAC) + GHRP:

• Synergistic GH release
• Different receptor targets
• Pulsatile pattern maintained

MK-677:

• Often used alone
• Oral convenience
• Continuous GH elevation

Regulatory Status

Aspect	MK-677	CJC-1295
FDA Status	Not approved	Not approved
WADA Status	Prohibited	Prohibited
DEA Schedule	Not scheduled	Not scheduled
Legal Status	Research chemical	Research chemical

Summary

Factor	MK-677	CJC-1295
Type	Small molecule (oral)	Peptide (injectable)
Mechanism	Ghrelin receptor	GHRH receptor
Evidence Level	Moderate	Moderate
Convenience	High (oral)	Lower (injection)
Side Effects	Appetite, glucose, water	Injection site, flushing
Approval Status	Not approved	Not approved

Key Takeaways

1. Different mechanisms: MK-677 mimics ghrelin; CJC-1295 mimics GHRH
2. Administration differs: MK-677 is oral; CJC-1295 requires injection
3. Neither is approved: Both are research chemicals without regulatory approval
4. MK-677 has more human data: Phase 2 trials completed but development stopped
5. MK-677 affects glucose: May worsen insulin sensitivity
6. CJC-1295 has limited data: Clinical program discontinued
7. Both prohibited in sport: WADA banned list includes both
8. Quality concerns: Unregulated sources have unknown purity

---

This comparison is for educational purposes only. Neither compound is approved by regulatory agencies. Products sold as research chemicals have uncertain quality and safety.